Our Focus Areas

We meticulously select cutting-edge technologies with strong commercial potential.

We do this, to meet global healthcare demands and strategically invest in their development to ensure their success.

Pharmaceuticals

Pharmaceuticals

BioTech

BioTech

Nutraceuticals

Nutraceuticals

R&D Tech / AI

R&D Tech / AI

MedTech

MedTech

Cube Labs at a glance

0

offices

0+M€

assets value

0+

universities in our network

0

startups

0

patents

0+

researchers in our network

Spearheading

democratization of healthcare

We aim to accelerate the democratization of the Life Science sector, making research, technologies, and tools more accessible to a wider audience.

This requires dismantling the barriers that restrict access to scientific information and fostering open innovation. By promoting the sharing of ideas and resources among institutions, companies, and individuals, we encourage new forms of collaboration and co-creation.

At Cube Labs, we are dedicated to driving meaningful change in healthcare, and we are excited about the future of innovation.

SUSTAINABILITY

REPORT

A document that reflects our ongoing commitment to social, environmental and economic sustainability and to the achievement of the Goals of the United Nations 2030 Agenda.



Achievements & Awards

Achievements & Awards

Cfi.co-2025_
motore_Italia_2025

Latest News

IP

BIODIAPERS: CONCESSO BREVETTO EUROPEO PER UN ARTICOLO ASSORBENTE INNOVATIVO CON FUNZIONE DI SEPARAZIONE E ISOLAMENTO DELLE FECI

Roma, 14 gennaio 2026 – Cube Labs S.p.A. (“Cube Labs” o “Società”) – venture builder italiano nel settore delle tecnologie sanitarie quotato su Euronext Growth…...
IP

LIPOVEXA OTTIENE UN BREVETTO NEGLI STATI UNITI PER UNA NUOVA PIATTAFORMA TERAPEUTICA PER IL TRATTAMENTO DEI DISORDINI METABOLICI

Roma, 9 gennaio 2026 – Cube Labs S.p.A. (“Cube Labs” o “Società”) – venture builder italiano nel settore delle tecnologie sanitarie quotato su Euronext Growth…...
IP

ORPHA BIOTECH: ACCOLTA LA DOMANDA DI BREVETTO EUROPEO PER INIBITORI DELL’INTERAZIONE DEI RECETTORI uPAR/FPRs

Roma, 7 gennaio 2026 – Cube Labs S.p.A. (“Cube Labs” o “Società”) – venture builder italiano nel settore delle tecnologie sanitarie quotato su Euronext Growth…...